Compare iShares JPMorgan USD Emerging Markets Bond ETF (EMB) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares JPMorgan USD Emerging Markets Bond ETF vs TransMedics Group Inc — how do they compare? iShares JPMorgan USD Emerging Markets Bond ETF trades at $91.04 (market cap $12.87B), while TransMedics Group Inc trades at $80.9 (market cap $2.74B). The key difference: iShares JPMorgan USD Emerging Markets Bond ETF is far larger — about 4.7× TransMedics Group Inc's market cap, and TransMedics Group Inc is more actively traded (949,331 versus 14,946,002). Which is the better fit depends on your goals — on Pluang, investors hold iShares JPMorgan USD Emerging Markets Bond ETF for 50 Days and TransMedics Group Inc for 24 Days on average.
| EMB | TMDX | |
|---|---|---|
Market Cap | $12.87B | $2.74B |
Volume | 14,946,002 | 949,331 |
Sector | Fixed Income | Health |
52-Week High | $97.74 | $150.42 |
52-Week Low | $90.14 | $61.99 |
Typical Hold Time | 50 Days | 24 Days |
Enterprise Value | — | $3.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EMB trades at $90.78, down 0.19% with a bearish technical signal from moving averages. The stock shows neutral oscillator readings with RSI at oversold levels. Recent dividend declarations of $0.41-$0.44 per share provide income support, though key valuation ratios remain unavailable for analysis. Technical indicators suggest the stock is testing support levels near $90-$91.
The outlook remains cautious given the bearish technical momentum and limited fundamental data visibility. Income investors may find value in the dividend yield, but the lack of current financial metrics and bearish technical signals suggest near-term pressure. Market sentiment appears mixed with fixed income ETFs seeing inflows while emerging market bonds face AI-driven yield pressures.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About iShares JPMorgan USD Emerging Markets Bond ETF
EMB invests in U.S. dollar-denominated sovereign debt from emerging market countries. It provides exposure to government bonds from dozens of nations like Turkey, Mexico, and Brazil, offering a way to seek higher yields and geographic diversification.
Read more on EMB →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
